spacer
home > ebr > spring 2003 > robotics in pharmaceutical research
PUBLICATIONS
European Biopharmaceutical Review

Robotics in Pharmaceutical Research

'Robot' is a Czech word meaning worker, from the play RUR: Rossums' Universal Robots by the Bohemian writer Karel Capek. The robot has since become an inspiration for science fiction writers and for engineers. Of course the science fiction vision of a robot is a mechanical man, but the reality we see in industry is simply a robotic arm. This is a versatile programmable manipulator, an integration of mechanics, electronics and software, designed interdependently to produce the mechanical equivalent of the computer - an undedicated machine unable to do anything until we program it.

In the pharmaceutical lab it is even less than that definition; the term 'robot' being applied to programmable liquid handlers. Drug development requires the screening of hundreds or thousands of samples and it is in this field that the robot arm is a vital tool. Such an automated screening system is called a 'high-throughput screening' (HTS) system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
By David N Sands, CEO and Founder of ST Robotics International

David N Sands was educated in London. He founded Sands-Whiteley Research and Development, which concentrated on advanced electronics and industrial automation using mini-computers and later microprocessors. David was a Department of Industry Consultant on microprocessors for many years. In 1982 the first robots were designed and Cyber Robotics, which was later sold to the Bibby Corporation, was formed the same year.

David wrote the first robot software, ROBOFORTH, in 1982 and designed the first robot controller in 1985. In 1989 he formed Sands Technology with Catherine George and ST-Monforte Robotics with Mathew Monforte in Trenton, New Jersey, in 1991. Sands Technology International Inc was formed in 1992 with Mathew Monforte as Vice President.
 

spacer
David N Sands
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Appointment of Angi Calkins as Chief Human Resources Officer

Philadelphia, PA – January 28, 2019. Leading biopharmaceutical services provider PCI Pharma Services (PCI) is pleased to announce the appointment of Angi Calkins as Senior Vice President and Chief Human Resources Officer. Angi joins PCI as the company experiences considerable growth and global expansion, currently with more than 3,500 associates, spanning eight locations comprised of 20 facilities across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement